Anelixis Therapeutics

Anelixis Therapeutics Overview

Founded 2012
Founded
Status Private
Employees 2
Employees
Latest Deal Type Later Stage VC
Investors 1

Anelixis Therapeutics General Information

Description

Operator of a biotechnology company intended to facilitate pre-clinical drug development of a novel anti CD40L antibody. The company's portfolio is focused on immune-modulatory drugs for neurodegenerative diseases with a focus on amyotrophic lateral sclerosis (ALS) and Alzheimer's Disease (AD), enabling medical practitioners and researchers to advance treatments that will have a meaningful impact on the lives of patients by helping them battle back their disease progression.

Contact Information

Formerly Known As
Anelixis Pharmaceuticals, Inc.
Ownership Status
Privately Held (backing)
Financing Status
Angel-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 300 Technology Square
  • Suite 400
  • Cambridge, MA 02139
  • United States
+1 (617) 000-0000

Anelixis Therapeutics Timeline

2017201820192020
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Anelixis Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Later Stage VC 18-Nov-2019 00.000 Completed Clinical Trials - General
10. Angel (individual) 15-May-2019 000 00.000 Completed Clinical Trials - General
9. Angel (individual) 25-Apr-2018 00.000 00.000 Completed Pre-Clinical Trials
8. Grant 01-Aug-2017 00000 00.000 Completed Pre-Clinical Trials
7. Angel (individual) 20-Jun-2017 00.000 00.000 Completed Pre-Clinical Trials
6. Grant 01-Jan-2017 000 Completed Pre-Clinical Trials
5. Grant 01-Aug-2016 000 Completed Pre-Clinical Trials
4. Grant 01-May-2016 00000 Completed Pre-Clinical Trials
3. Grant 01-Jan-2016 $1.2M Completed Pre-Clinical Trials
2. Grant 01-Jan-2015 $1M Completed Pre-Clinical Trials

Anelixis Therapeutics Competitors (18)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing
Amount
Yumanity Therapeutics Venture Capital-Backed Boston, MA 00 00000 00000000000 00000
000000 00000000000 Venture Capital-Backed Cambridge, MA 0 000.00 00000000000 000.00
000000000 Formerly VC-backed South San Francisco, CA 00 00000 000000000 00000
0000000 Venture Capital-Backed Framingham, MA 0 0000 0000000000 0 0000
0000000 Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000

Anelixis Therapeutics Executive Team (4)

Name Title Board Seat Contact Info
Steven Perrin Ph.D Co-Founder, President, Chief Executive Officer & Board Member
Maeve McNally Co-Founder, Director Program Management & Executive Assistant to CEO
Pamela Gustafson Vice President of Clinical Operations and Compliance & Board Member
Walter Ogier Executive Chairman

Anelixis Therapeutics Board Members (10)

To view Anelixis Therapeutics‘s full board member team, request access »
Name Representing Role Since
Augie Nieto Anelixis Therapeutics Chairman 000 0000
Lynne Nieto Anelixis Therapeutics Board Member 000 0000
Pamela Gustafson Anelixis Therapeutics Vice President of Clinical Operations and Compliance & Board Member 000 0000
Steven Perrin Ph.D Anelixis Therapeutics Co-Founder, President, Chief Executive Officer & Board Member 000 0000
Walter Ogier Self Executive Chairman 000 0000

5 Former Board Members

Anelixis Therapeutics Investors (1)

To view Anelixis Therapeutics‘s full investor history, request access »
Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
BVF Partners Hedge Fund Minority 000 0000 000000 0

Ready to get started?

Request a free trial